
usd sep pm et
summari compani primarili focus discoveri develop commerci
price-to-earnings oper ep
sale upward trend free cash flow off-set
compani signific revenu concentr
jakafi high spend
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
expect revenu expand
billion sale growth jakafi
five-year revenu compound-annual-growth-rate
reflect rapid growth sale jakafi
first fda-approv
although signific revenu
concentr jakafi anticip
consider competit threat jakafi
domin posit treatment
myelofibrosi mf polycythemia vera pv
least next sever year addit
key patent ruxolitinib compound
name jakafi valid decemb
also develop ruxolitinib topic
cream atop dermat vitiligo
although manag lean toward
commerci ruxolitinib cream
 wonder sharehold would
better serv collabor
commerci effort given differ
ruxolitinib cream therapi
current market exampl
atop dermat highli contest
indic mf uncontest
june plenti capac
engag opportunist
opinion share appropri
reflect valu compani mid-
late-stag pipelin asset exist
substanti relianc drug jakafi
late-stag pipelin candid believ
ruxolitnib cream itacitinib treatment
naiv gvhd graft versu host diseas
potenti futur sale expect
phase trial data readout itacitinib
ruxolitinib cream atop
dermat posit data
readout like quickli follow
regulatori submiss june
robust pipelin phase ii trial
even earlier stage program
current assign littl valu
risk opinion target price includ
commerci under-perform jakafi
clinic develop setback unfavor
target price base
ep estim forward price-to-earnings
multipl one-year averag
significantli peer
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president head
corpor overview incyt corpor biopharmaceut compani primarili focus
discoveri develop commerci proprietari oncolog hematolog therapeut
compani primari product jakafi compound name ruxolitinib compani first
commerci therapeut jakafi first approv food drug administr fda
novemb treatment patient intermedi highrisk myelofibrosi mf
approv decemb treatment patient polycythemia vera pv
inadequ respons intoler hydroxyurea myelofibrosi mf polycythemia vera pv
rare blood cancer year end decemb jakafi jakavi compris
inci product revenu accord inci ceo earn call medicar make
 jakafi sale
market jakafi iclusig europ also receiv royalti revenu sale
jakavi name jakafi outsid olumi baricitinib jakavi market novarti
ag olumi market compani
competit ruxolitinib composit matter patent expir decemb mean sale
jakafi jakavi like safe biosimilar competit least could like
extend patent protect ruxolitnib increment patent septemb see
substanti threat sale jakafi jakavi come sever year least
sever aspir competitor tri develop therapeut treat mf pv progress difficult
success competitor far would celgen corp celg receiv fda approv
august fedratinib mf howev expect fedratinib second-lin therapi mf
especi given black box warn encephalopathi concern toxic profil
olumi royalti revenu repres second valuabl asset jakafi receiv tier
royalti global sale howev olumi compet highli competit market
treatment moderate-to-sever rheumatoid arthriti drug black box label stop
fund joint develop olumi focu promis
opportun nonetheless estim olumi could provid million royalti revenu
pipelin larg number clinic candid develop although dont current see
combin clinic candid gener much revenu ruxolitinib next decad
june clinic candid closest commerci itacitinib parsaclisib
pemigatinib addit indic ruxolitinib believ ruxolitnib cream atop
dermat vitiligo itacitinib treatment nave gvhd graft versu host diseas
potenti futur sale
ruxolitinib cream repres diverg inci tradit focu oncolog hematolog
ruxolitinib cream aim treat atop dermat vitiligo fall inflamm
autoimmun iai addit inci iai franchis aim target much broader popul
approxim million potenti patient wherea mf pv rare diseas patient
popul small unlik jakafi ruxolitinib cream face signific competit primarili
atop dermat indic despit differ manag appear lean toward
independ commerci ruxolitinib cream expect phase data readout
ruxolitinib cream atop dermat earli although approv larg expect given strong
phase ii result initi phase trial ruxolitinib cream vitiligo
think sale itacitinib success launch could reach million
estim new patient year affect treatment nave gvhd success
itacitinib like depend much effect treat patient
corticosteroid corticosteroid establish rel inexpens first line treatment
financi trend total revenu billion billion product
revenu compound annual growth rate compound-annual-growth-rate revenu past five year
reflect rapid sale growth jakafi approv fda revenu growth
deceler expect compound-annual-growth-rate year end ep
adjust ep june gener trailing-twelv month free cash
flow defin cash oper less capit expenditur million billion
cash cash equival market secur addit typic maintain low level
debt suggest us suffici financi capac fund oper make
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc septemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
measur taken legisl regulatori
bodi lower drug price
democrat appear motiv
address drug price still think
suffici bipartisan impetu effect
signific chang near futur
anoth sourc price pressur drug
manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price especi sinc
major pbm merg major insur
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
fda-approv biosimilar
manufactur aggress use patent
law commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
year-to-d septemb
compar rise valu
 composit index
declin
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newli approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
recent year mega-d
announc bristol-my
squibb acquisit celgen
celg acquisit
botox manufactur allergan matur
biopharmaceut firm look off-set
lost revenu expir patent fail
ventur promis late-stag pipelin
addit exampl think gilead
scienc could
interest larg collabor
agreement biotechnolog compani
low debt level attract valuat
rel industri make
think investor interest biotechnolog
stock mute recent high drug
price come heighten scrutini
 polit apparatu last
year despit talk lower drug
price seen particularli sever
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra initi coverag incyt corpor hold
rate begin coverag target price
reflect forward price-to-earnings ratio earn estim ep
estim opinion share
appropri captur valu compani mid- late-stag
pipelin asset exist commerci oper especi
substanti relianc drug jakafi product revenu
late-stag pipelin asset forecast ruxolitnib cream atop
dermat vitiligo itacitinib treatment nave gvhd graft
versu host diseas potenti futur sale expect phase
trial data readout itacitinib end ruxolitinib cream
atop dermat posit data readout like
quickli follow regulatori submiss although compani robust
pipelin hesit assign valu early-stag program /kevin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
